This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dahan, A. Search for Related Content PubMed PubMed Citation Articles by Dahan, A. Social Bookmarking                         What's this?

Opioid-induced respiratory effects: new data on buprenorphine

Department of Anesthesiology, Leiden University Medical Center, Leiden, a.dahan{at}lumc.nl

When selecting the appropriate long-acting opioid to treat cancer pain, both analgesic efficacy and safety need consideration. Generally, opioids are well tolerated. However, of opioid-typical adverse events, respiratory depression is especially important because of the risk of a fatal outcome. Although all potent opioid analgesics act via the µ-opioid receptor system, they differ in how they affect respiratory control. Recently, the respiratory effects of fentanyl (1 - 7 µg/kg) and buprenorphine (0.7 - 9 µg g/kg) were compared in healthy opioidnaïve volunteers. Fentanyl produced dose-dependent depression of respiration with apnoea at doses 3 µg/kg, while buprenorphine caused depression that levelled at ~50% of baseline with doses 2 µg/kg. These findings indicate the occurrence of a ceiling in the respiratory depression induced by buprenorphine but not by fentanyl. Surprisingly few studies have addressed the clinically important ability to reverse the respiratory effects of opioids. A recent assessment of the naloxone dose required to reverse 0.2 µg intravenous buprenorphine-induced respiratory depression in healthy opioid-naïve volunteers, found that the accumulated naloxone dose causing 50% reversal of respiratory depression was 1.200.32 µg/70 kg (given in 30 min); 80% reversal was observed at 2.500.60 µg/70 kg (given in 30 min). At greater buprenorphine doses, full reversal is observed when the duration of naloxone infusion is increased. These findings indicate the need for a continuous rather than bolus administration of naloxone to reverse the respiratory effects of buprenorphine. In conclusion, buprenorphine is more favourable compared with fentanyl in respect to ventilatory control. Buprenorphine causes limited respiratory depression with a ceiling effect at higher doses, while fentanyl causes dose-dependent respiratory depression with apnoea at high dose levels. In the rare instance of respiratory depression, reversal is possible with a sufficient and continuous infusion of naloxone.

Key Words: apnoea • buprenorphine • ceiling effect • fentanyl • naloxone • opioid • respiratory depression

Palliative Medicine, Vol. 20, No. 8 suppl, 3-8 (2006)
DOI: 10.1191/0269216306pm1126oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?